Zydus’ New Drug Discovery, ‘Desidustat’, Licensed to China Medical System Holdings Receives Approval from NMPA of China

Zydus Lifesciences Ltd. announced that its innovative drug Desidustat tablets, licensed to the subsidiary of China Medical System Holdings Limited, has been approved for renal anaemia in China by the National Medical Products Administration of China (NMPA). Desidustat tablets are administered orally and represent a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients. The drug is discovered, developed, and marketed by Zydus in India under the brand name Oxemia™. More than 1 lac CKD patients in India have been successfully treated with Oxemia™ since its launch in 2022. There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China.